Short Answer

Johnson & Johnson is likely to mention Rybrevant during its next earnings call on Oct 13, 2026, with the market pricing this outcome at 74.0%.

1. Market Behavior & Drivers

No reported development coincides with the market’s largest move, a 58.0 percentage point spike on September 15. The subsequent 20.0 point drop on September 21 and 36.0 point spike on September 23 also lack specific drivers in the available information. The price has trended consistently upward from a low of 2.0% to a current probability of 93.0%.

The 12.0 point increase on September 24 is linked to a significant but unconfirmed signal from a separate prediction market focused on Johnson & Johnson and China. Research could not validate the catalyst behind that related market's activity. The overall market sentiment reflects high conviction ahead of the company’s scheduled October 13 earnings report.

Rybrevant mentions are likely due to significant 2026 clinical milestones.
Litigation discussions are expected, driven by the proposed $5.5 billion talc settlement.

Who Wins and Why

Outcome	Market	Model	Why
Procedure	93.0%	90.8%	JNJ regularly discusses its operational procedures and strategic execution during earnings calls.
Ottava	65.0%	54.8%	Updates are expected regarding Ottava's development or market strategy.
Tecvayli	64.0%	53.6%	Discussion will likely cover Tecvayli's commercial launch progress and uptake.
Caplyta	69.0%	59.7%	JNJ may provide updates on Caplyta's sales performance or market penetration.
Rybrevant	74.0%	66.0%	Discussion is anticipated on Rybrevant's market performance, expansion, or clinical progress.

Current Context

Johnson & Johnson's Q3 2026 earnings are expected with growth focus. The company is scheduled to report results before market open on Tuesday, October 13, 2026, with calendar sources showing conflicting call times of 6:20 a.m. ET and an expected 8:30 a.m. ET call; investors should verify the official J&J announcement ^[1]^[2]. Current estimates cluster around adjusted EPS of $2.95–$2.96 and revenue of $25.36 billion for the quarter, though one estimate lists $2.88, indicating moving consensus data ^[1]^[3]^[4]. Management will likely emphasize continued growth despite STELARA biosimilar erosion, citing 6.5% 2026 adjusted operational sales growth, 7.3% adjusted EPS growth, and the company's first annual revenue above $100 billion ^[3]^[5]. J&J has also described 2027 as potentially stronger than 2026 ^[5]. Sustained quarterly sales near or above $25 billion, a level not previously reported by J&J, will be a key factor for the $100 billion annual revenue goal ^[3]^[6].

Oncology momentum, new products balance STELARA erosion and risks. Positive talking points are likely to include oncology product momentum (DARZALEX, CARVYKTI, TECVAYLI), new launches and pipeline catalysts (IMAAVY, INLEXZO, nipocalimab, milvexian), accelerating MedTech growth (OTTAVA, electrophysiology products), and stable procedure volumes ^[3]^[5]. Potential risks for discussion involve continued STELARA price and volume pressure, litigation and restructuring costs, foreign-exchange effects, tariffs, margins, regulatory or clinical uncertainty, and the need to demonstrate uptake of new products ^[3]^[7]. Quantitative prediction signals lean toward an earnings beat, with Earnings Whispers indicating a $2.96 consensus and a positive post-earnings drift signal, while fffinstill reports a 95% model-implied beat probability; these are model estimates, not official forecasts ^[1]^[8]. A Kalshi-linked prediction market shows a 79% implied probability for a "Litigation" contract, but its internal text is inconsistent regarding the settlement rule ^[9].

Call date unconfirmed; key themes would involve growth and pipeline. As of September 28, 2026, retrieved evidence does not establish a verified Johnson & Johnson earnings call on October 13, 2026; official J&J investor relations or transcript sources do not confirm the date ^[10]^[11]^[12]^[13]^[14]^[15]. The most recent JNJ outlook centered on Q2 2026, where consensus adjusted EPS was $2.85 versus $2.77 a year earlier, and full-year adjusted EPS guidance had been raised to $11.55 after a Q1 adjusted-EPS beat ^[11]. If an earnings call occurs around October 13, management is most likely to emphasize continued growth from Darzalex and Tremfya, quantify or explain ongoing STELARA biosimilar erosion, reaffirm or update the $11.55 full-year adjusted-EPS framework, and discuss pipeline/launch progress for products such as Carvykti, Rybrevant, or Ottava ^[11]. Confidence is medium for the first three themes and low for any specific pipeline mention. J&J's recent earnings call pattern typically discusses sales, adjusted EPS, full-year guidance, pipeline, capital allocation, and business separations ^[16]^[7].

Sources (16)

2. Price Chart

Historical Price (Probability)

Outcome probability

Date

3. Significant Price Movements

Notable price changes detected in the chart, along with research into what caused each movement.

Outcome: Tariff

📉 September 28, 2026: 51.0pp drop

Price decreased from 90.0% to 39.0%

What happened: The provided web research does not corroborate a 51.0 percentage point drop in the prediction market for Johnson & Johnson's "Tariff" mentions on September 28, 2026 ^[1]^[2]^[3]^[4]^[5]^[6]^[7]. Without evidence that such a market movement occurred, it is not possible to identify a primary driver. While Johnson & Johnson had previously noted tariffs as a MedTech cost and margin pressure, expected to characterize tariff exposure as manageable, and the next earnings call is scheduled for October 13, 2026, no specific news, social media activity, or market structure factors on September 28, 2026, correlate with the reported drop ^[8]^[9]^[10]^[11]. Consequently, social media was irrelevant, as no specific activity appeared to lead, coincide with, or lag an uncorroborated price movement.

Outcome: Litigation

📉 September 27, 2026: 71.0pp drop

Price decreased from 90.0% to 19.0%

What happened: The primary driver for the 71.0 percentage point drop in the "Litigation" outcome on September 27, 2026, appears to be a market re-evaluation based on a shift in focus towards Johnson & Johnson's growth drivers and pipeline. While the proposed $5.5 billion talc settlement, announced on July 27, 2026, likely inflated the implied probability of "Litigation" being mentioned ^[12], traditional news throughout September 2026 emphasized J&J's "path to double-digit growth" ^[13] and positive data for TREMFYA and CARVYKTI ^[14]^[15]. This sustained emphasis on operational performance and future prospects, framed as offsetting litigation and patent cliff concerns, likely led to investors adjusting expectations regarding the upcoming earnings call's primary discussion points. Social media was irrelevant, as no specific posts correlating with the price movement were identified.

Outcome: Rybrevant

📉 September 26, 2026: 36.0pp drop

Price decreased from 86.0% to 50.0%

What happened: The primary driver for the reported 36.0 percentage point drop in the "Rybrevant" outcome on September 26, 2026, could not be identified through the available research. No specific social media activity from key figures or viral narratives, official press releases, or market structure events correlating with this precise date and magnitude of movement were found ^[16]. While Rybrevant's PAPILLON OS data did not reach statistical significance, this news was available earlier and did not specifically coincide with the reported market drop ^[17]. Social media was irrelevant to this reported price movement, as no correlating activity was identified in the provided sources.

Outcome: Tecvayli

📉 September 25, 2026: 72.0pp drop

Price decreased from 93.0% to 21.0%

What happened: The provided research does not corroborate a 72.0 percentage point drop in a prediction market for "Tecvayli" mentions on Johnson & Johnson's next earnings call on September 25, 2026 ^[18]^[19]. Instead, available evidence indicates positive news around that date, with Johnson & Johnson reporting sustained survival benefits for TECVAYLI in multiple myeloma from the MajesTEC-3 study, which would typically drive a positive sentiment rather than a sharp drop ^[20]^[21]^[22]. J&J's stock movement around September 25, 2026, was modest or positive ^[14]^[23]^[15]. Therefore, there is no evidence of social media or traditional news driving the described price movement, and it appears irrelevant given the uncorroborated event.

Outcome: China

📈 September 24, 2026: 72.0pp spike

Price increased from 22.0% to 94.0%

What happened: The 72.0 percentage point spike in the Johnson & Johnson "China" prediction market on September 24, 2026, cannot be validated by the provided web research, which explicitly states that this specific market signal and any related news/social media catalyst cannot be confirmed ^[19]. Consequently, no primary driver from social media activity, traditional news, or market structure can be identified for this unverified price movement on that date. The available information for September 24, 2026, notes JNJ stock closed at $270.68 and ETFs were net sellers, but offers no indication of a "China"-related price surge or pertinent social media posts ^[24]^[25]. Therefore, social media was irrelevant as a driver for this unsubstantiated event.

Sources (25)

4. Market Data

Contract Snapshot

This market, asking what Johnson & Johnson will say during their next earnings call, begins on Oct 13, 8:30 am EDT. The provided content does not detail the specific conditions that trigger a YES or NO resolution for any of the listed topics like Tecvayli or Halda Therapeutics. The maximum payout date for the market is March 31, 2027.

Available Contracts

Market options and current pricing

Outcome bucket	Yes (price)	No (price)	Last trade probability
Procedure	$0.93	$0.08	93%
Nipocalimab / Lupus	$0.38	$0.70	89%
Firefly Bio	$0.90	$0.20	80%
Rybrevant	$0.75	$0.36	74%
Litigation	$0.73	$0.36	70%
Caplyta	$0.79	$0.32	69%
Ottava	$0.93	$0.14	65%
Darzalex Faspro	$0.80	$0.27	64%
Tecvayli	$0.65	$0.41	64%
China	$0.92	$0.09	57%
Halda Therapeutics	$0.57	$0.49	50%
AI / Artificial Intelligence	$0.49	$0.57	49%
Tariff	$0.88	$0.19	39%
Administration	$0.35	$0.73	36%
Gene Therapy	$0.13	$0.95	13%
Vaccine	$0.12	$0.92	10%

Market Discussion

The market discussion primarily focuses on the likelihood of Johnson & Johnson mentioning Tecvayli, Halda Therapeutics, or AI/Artificial Intelligence during their next earnings call. Tecvayli is considered the most probable topic at 64%, despite a significant 20 percentage point drop in its perceived likelihood. Halda Therapeutics and AI/Artificial Intelligence are seen as roughly equally likely, both hovering around a 50% chance, with the market's "arguments" for YES versus NO outcomes expressed through the current odds and contract prices.

5. Trust Index

The market subject can determine its own outcome.

Integrity risk· Outcome control

How it adds up

Integrity80% of score39High Risk

Trade quality20% of score27Avoid

Includes the cost to trade: a $1,000 order can't be filled here because the order book is too thin.

Trust score36High Risk

Market integrity (20) is below its safety floor, but the score was already under that cap's ceiling, so no cap applied.

Weighted blend with hard caps — a critically weak safety pillar, or a severe trading anomaly, caps the total regardless of the rest. Full methodology · About the Trust Index

Trust profile

Integrity6 screens run · 1 doesn't apply · 3 awaiting data

6. What recent developments in talc litigation could force a discussion of financial reserves on Johnson & Johnson's Q3 2026 earnings call?

Proposed talc claims resolution	$5.5 billion (July 27, 2026 announcement) ^[1]^[2]
Number of talc claims	Approximately 76,000 ^[1]^[2]
Prior talc reserve reversal	Approximately $7 billion (2025) ^[3]

Johnson & Johnson's proposed talc settlement will be a key Q3 2026 discussion. The company announced a proposed $5.5 billion resolution on July 27, 2026, intended to address approximately 76,000 ovarian-talc claims ^[1]^[2]. This voluntary settlement is expected to be a major topic regarding financial reserves during the Q3 2026 earnings call ^[1]^[2]. The agreement is conditional on a 95% participation rate, introducing execution risks and complex accounting considerations for the company ^[1]^[4]. Furthermore, the proposed resolution is uncapped, meaning its actual value could exceed $5.5 billion depending on the final participation rate ^[1]^[4].

Q3 disclosures will address specific accounting treatments and financial exposure. Johnson & Johnson's Q3 disclosures will likely need to detail specific accounting treatments, the timing of accruals, and any remaining financial exposure ^[4]^[1]. Management may face questions about whether this commitment requires a new GAAP accrual or an adjustment to existing reserves, how much will be recognized in Q3 versus later periods, and if the 95% threshold or uncapped participation might alter the ultimate liability ^[2]^[4]^[1]. This issue carries significant materiality, especially considering the company's recent history with reserves, including a reversal of approximately $7 billion in previously recorded talc reserves in 2025 following a prior failed bankruptcy attempt ^[3]. Additionally, Q2 2026 financial reports indicated $267 million in litigation-related expenses for the quarter and $597 million year-to-date ^[5]. The conditions tied to the new settlement, such as the 95% participation threshold, continue to present execution risk that could drive further discussion on reserves during the Q3 2026 earnings call ^[1]^[4].

Sources (5)

7. How do Q3 2026 revenue and margin forecasts from major analyst firms like Goldman Sachs and Morgan Stanley break down to support the consensus EPS estimate of ~$2.95?

Q3 2026 Consensus EPS	$2.43 (11 analysts, range $2.31-$2.49) ^[1]
Q3 2026 Consensus Revenue	$25.2 billion (range $25.0-$25.3 billion) ^[1]
Q2 2026 Adjusted EPS	$2.90 ^[2]^[3]

Analyst estimates report a Q3 2026 consensus EPS of $2.43. The provided source indicates a consensus earnings per share (EPS) of $2.43, with individual analyst forecasts ranging from $2.31 to $2.49, based on insights from 11 analysts ^[1]. This differs from the approximately $2.95 EPS figure referenced. The consensus revenue forecast for Q3 2026 stands at $25.2 billion, with projections spanning from $25.0 billion to $25.3 billion ^[1]. The supplied results do not include a Goldman Sachs-specific Q3 2026 forecast, and while Morgan Stanley maintains an Overweight rating, the source does not provide specific Q3 revenue, margin, or EPS forecasts for Morgan Stanley ^[4].

Consensus EPS of $2.43 is supported by specific financial estimates. To align with the reported consensus EPS of $2.43, the estimates include a consensus EBITDA of $8.4 billion, EBIT of $6.2 billion, and net income of $7.4 billion ^[1]. For historical context, Johnson & Johnson's Q2 2026 performance included revenue of $25.310 billion, a gross profit of $17.259 billion resulting in a 68.2% gross margin, and adjusted net income of $7.081 billion, representing 28.0% of sales ^[2]^[3]. The adjusted EPS for Q2 2026 was $2.90 ^[2]^[3]. Subsequent to its Q2 2026 results, Johnson & Johnson updated its full-year 2026 guidance, raising reported-sales guidance to a midpoint of $101.1 billion, reflecting 7.3% growth. The company also increased its adjusted EPS guidance by $0.13 to $11.68, an 8.2% growth at the midpoint ^[2].

Sources (4)

8. How do the 2026 pipeline milestones for Johnson & Johnson's nipocalimab and Rybrevant compare to key immunology catalysts from competitors like Pfizer and Merck?

Nipocalimab Lupus Phase 2 (Week 24)	SRI-4 response of 53.5% vs 46.7% for placebo ^[1]
V940/mRNA-4157 FDA Approval Probability	95% by Jan 1, 2028 (as of Sept 17, 2026) ^[2]
V940/mRNA-4157 BLA Submission Probability	88% by June 30, 2027 ^[2]

Johnson & Johnson delivered significant clinical milestones for nipocalimab and Rybrevant in 2026. Nipocalimab, an immunology asset, demonstrated positive Phase 2 JASMINE lupus data, successfully meeting its Week 24 primary endpoint with an SRI-4 response of 53.5% compared to 46.7% for placebo. Week 52 data further reinforced these findings, showing a response of 53.6% versus 39.7% ^[1]. Furthermore, J&J expanded nipocalimab's immunology platform by presenting 12 abstracts for generalized myasthenia gravis at the European Academy of Neurology (EAN) 2026 Congress ^[3]^[4]. Concurrently, Rybrevant, a key oncology asset, reached a significant 2026 milestone with the presentation of final overall-survival results from its Phase 3 PAPILLON study ^[5].

Competitor milestones vary, with Merck focused on regulatory events for V940/mRNA-4157. In contrast to Johnson & Johnson's 2026 delivery of clinical efficacy and survival data for nipocalimab and Rybrevant, the Merck-related catalyst for intismeran autogene (V940/mRNA-4157) with pembrolizumab centered on future regulatory achievements rather than new clinical efficacy data in 2026 ^[1]^[5]^[2]. Prediction markets on September 17, 2026, indicated a 95% probability of FDA approval for V940/mRNA-4157 before January 1, 2028, and an 88% probability for its Biologics License Application (BLA) submission or acceptance by June 30, 2027 ^[2]. A direct comparison with Pfizer's 2026 immunology catalysts cannot be made due to insufficient available evidence ^[6]^[7].

Sources (7)

9. Is weekly or monthly U.S. hospital surgical procedure volume data for Q3 2026 available to forecast J&J's MedTech device performance ahead of the call?

Q3 2026 US Hospital Surgical Data	Not available in search results ^[1]^[2]
Johnson & Johnson MedTech Areas	Cardiovascular, Orthopaedics, Surgery, Vision ^[2]
Kalshi Market Resolution	Based on specific outcome words said during J&J earnings call, not MedTech surgical volume or device revenue ^[1]^[3]^[4]^[5]^[6]

Weekly or monthly U.S. hospital surgical volume data for Q3 2026 is unavailable. The provided search results do not include weekly or monthly U.S. hospital surgical procedure volume data for the third quarter of 2026 ^[1]^[2]. The available information lacks specific procedure-volume metrics, hospital utilization dashboards, or dated surgical data from July through September 2026 that could be used to project Johnson & Johnson's MedTech device performance ^[1]^[2].

J&J's public information and market predictions do not forecast Q3 2026 MedTech. While Johnson & Johnson identifies its MedTech areas as Cardiovascular, Orthopaedics, Surgery, and Vision, and references a second-quarter 2026 earnings report, the supplied information does not offer Q3 2026 procedure-volume indicators or a specific MedTech forecast ^[2]. Furthermore, the relevant Kalshi market is structured to resolve based on whether a specific outcome word is spoken by a Johnson & Johnson representative during their earnings call, including the Q&A segment, rather than being directly tied to MedTech surgical volume or device revenue ^[1]^[3]^[4]^[5]^[6].

Sources (6)

10. What Q3 2026 sales data for CARVYKTI and TECVAYLI supports the narrative that new oncology drugs can offset STELARA's revenue decline?

CARVYKTI Q2 2026 Sales	$657 million, up 49.4% year over year ^[1]^[2]^[3]
TECVAYLI Q2 2026 Sales	$260 million, up 56.5% year over year ^[1]^[2]^[3]
STELARA Q2 2026 Sales	$740 million, down 55.2% year over year ^[4]

Q3 2026 sales data for CARVYKTI and TECVAYLI are not yet available. As of September 28, 2026, Q3 2026 sales data for CARVYKTI and TECVAYLI were not yet available. The relevant J&J earnings call is scheduled for October 13, 2026, where these figures are expected ^[1]^[2]. Consequently, actual Q3 figures have not yet been reported to directly support the narrative that new oncology drugs can offset STELARA's revenue decline ^[1]^[2]. Although a prediction market exists for the October 13 call, it focuses on the mention of a specific term, not necessarily Q3 sales discussions ^[5]^[6]. The latest reported Q2 2026 data, however, provides supporting trend information.

Newer oncology drugs show strong growth amidst STELARA's significant decline. In Q2 2026, worldwide CARVYKTI sales reached $657 million, representing a 49.4% year-over-year increase, and TECVAYLI sales were $260 million, up 56.5% year over year ^[1]^[2]^[3]. For the first half of 2026, CARVYKTI sales totaled $1.254 billion (up 55.1%) and TECVAYLI sales were $462 million (up 45.5%). Together, these two drugs generated $1.714 billion in first-half sales, an increase of $592 million from the prior-year period ^[4]. This growth occurred concurrently with a significant decline in STELARA sales, which were $740 million in Q2 2026, down 55.2% year over year, and $1.396 billion for the first half, a 57.4% decrease ^[4].

J&J's Innovative Medicine segment demonstrates growth despite STELARA headwinds. J&J reported its Innovative Medicine operational sales grew 6.8% in Q2 2026, primarily driven by products including CARVYKTI and TECVAYLI ^[1]^[2]. STELARA represented an approximate 760-basis-point headwind for this segment ^[1]^[2]. These figures illustrate the significant erosion that these newer oncology products are helping to offset. Management further demonstrated confidence by raising full-year 2026 operational-sales guidance to a midpoint of $100.6 billion, with a range of $100.3–$100.9 billion ^[1]^[2].

Sources (6)

11. What Could Change the Odds

Key Catalysts

Johnson & Johnson is scheduled to host its third-quarter 2026 earnings conference call on Tuesday, October 13, 2026, at 8:30 a.m. ET ^[1]^[2]^[3]^[4]. Analyst consensus for Q3 2026 estimates approximately $25.2 billion in revenue and $2.43 in EPS, with an EPS range of $2.31–$2.49 ^[5].

Management is expected to discuss progress in Innovative Medicine, driven by Darzalex, Carvykti, Tremfya, and Rybrevant/Lazcluze, and MedTech performance ^[6]^[7]^[8]. The discussion will also cover the impact of Stelara biosimilar competition and updates on the orthopedics business separation ^[6]^[7]^[8]. Key bullish catalysts include ongoing strong oncology and immunology segment growth and recent positive clinical data for Tremfya (axial-PsA) and Carvykti (early-line myeloma) ^[6]^[9]^[8].

Bearish risks encompass talc-related litigation and potential margin pressure from restructuring ^[6]^[9]^[8]. The portfolio transition poses a risk: Polymarket's Q2 2026 context indicated resilient Darzalex and Tremfya demand only partly offset sharp Stelara revenue erosion from biosimilar competition, against a consensus EPS bar of $2.85 ^[10]^[11]. Investors should monitor Stelara erosion, pricing/volume, biosimilar timing, and whether new-product growth sufficiently preserves raised guidance ^[10]^[11]. Polymarket's prior indexed earnings-mentions markets are stale and resolved; no live October 13, 2026 forecast or EPS market with current odds was retrieved ^[11]^[12]^[13]^[14]^[15].

Key Dates & Catalysts

Expiration: March 31, 2027
Closes: March 31, 2027

Sources (15)

12. Keep Exploring

More Earnings markets See more earnings setups in the same theme. Browse all Mentions markets Keep exploring adjacent mentions markets. Track this in the app Open the live app flow and keep following this market in real time.

What will Johnson & Johnson say during their next earnings call?

Short Answer

1. Market Behavior & Drivers

Who Wins and Why

Current Context

2. Price Chart

Historical Price (Probability)

3. Significant Price Movements

Outcome: Tariff

📉 September 28, 2026: 51.0pp drop

Outcome: Litigation

📉 September 27, 2026: 71.0pp drop

Outcome: Rybrevant

📉 September 26, 2026: 36.0pp drop

Outcome: Tecvayli

📉 September 25, 2026: 72.0pp drop

Outcome: China

📈 September 24, 2026: 72.0pp spike

4. Market Data

Contract Snapshot

Available Contracts

Market options and current pricing

Market Discussion

5. Trust Index

6. What recent developments in talc litigation could force a discussion of financial reserves on Johnson & Johnson's Q3 2026 earnings call?

7. How do Q3 2026 revenue and margin forecasts from major analyst firms like Goldman Sachs and Morgan Stanley break down to support the consensus EPS estimate of ~$2.95?

8. How do the 2026 pipeline milestones for Johnson & Johnson's nipocalimab and Rybrevant compare to key immunology catalysts from competitors like Pfizer and Merck?

9. Is weekly or monthly U.S. hospital surgical procedure volume data for Q3 2026 available to forecast J&J's MedTech device performance ahead of the call?

10. What Q3 2026 sales data for CARVYKTI and TECVAYLI supports the narrative that new oncology drugs can offset STELARA's revenue decline?

11. What Could Change the Odds

Key Catalysts

Key Dates & Catalysts

Prediction Markets

Public Markets

Developers

Company

Short Answer

Who Wins and Why

Current Context

Historical Price (Probability)

Outcome: Tariff

📉 September 28, 2026: 51.0pp drop

Outcome: Litigation

📉 September 27, 2026: 71.0pp drop

Outcome: Rybrevant

📉 September 26, 2026: 36.0pp drop

Outcome: Tecvayli

📉 September 25, 2026: 72.0pp drop

Outcome: China

📈 September 24, 2026: 72.0pp spike

Contract Snapshot

Available Contracts

Market options and current pricing

Market Discussion

Key Catalysts

Key Dates & Catalysts

What will Amazon say during their next earnings call?

What will Costco say during their next earnings call?

What will Hewlett Packard Enterprise say during their next earnings call?

What will Snowflake say during their next earnings call?

What will Ross Stores say during their next earnings call?

What will Zoom say during their next earnings call?

What will BJ's Wholesale say during their next earnings call?

What will Amer Sports say during their next earnings call?

Prediction Markets

Public Markets

Developers

Company